2021 USPSTF Recommendation Boosted Colorectal Cancer Screening
By Lori Solomon HealthDay Reporter
FRIDAY, Oct. 4, 2024 -- Uptake of colorectal cancer (CRC) screening increased after the 2021 U.S. Preventive Services Task Force (USPSTF) recommendation that all average-risk individuals aged 45 to 49 years should receive screening, according to a study published online Oct. 3 in JAMA Network Open.
Sunny Siddique, M.P.H., from the Yale School of Public Health in New Haven, Connecticut, and colleagues evaluated changes in CRC screening uptake among average-risk individuals aged 45 to 49 years following the 2021 USPSTF recommendation. The analysis included claims data from 10 million commercially insured Blue Cross Blue Shield beneficiaries (2017 through 2022).
The researchers found that mean screening uptake increased from 0.50 to 1.51 percent from before the recommendation to after the recommendation. While there was an absolute change of 1.01 percentage points, there was no significant relative change. Beneficiaries residing in areas with the highest socioeconomic status experienced the largest absolute change in screening (1.25 percentage points versus 0.75 percentage points for areas with the lowest socioeconomic status), but these relative changes were not significant. After the recommendation, the screening uptake rate increased fastest among average-risk beneficiaries residing in the areas with highest socioeconomic status (0.24 percentage points every two months) and metropolitan areas (0.20 percentage points every two months).
"Although CRC screening was expectedly higher among high-risk individuals, the twofold increase in screening among average-risk beneficiaries suggests a shift in the screening paradigm of this newly included age group," the authors write.
Two authors disclosed ties to the pharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted October 2024
Read this next
Multitarget Stool DNA Tests More Costly Than FIT for Colorectal Cancer Detection
WEDNESDAY, May 14, 2025 -- Multitarget stool DNA test (MSDT)- and next-generation MSDT (N-G MSDT)-based screening have higher costs per detected advanced neoplasia case or early...
Digestive Disease Week, May 3-6
Digestive Disease Week, the annual meeting sponsored by the American Association for the Study of Liver Diseases, American Gastroenterological Association, American Society for...
Early-Life Exposure to Certain Bacteria May Impact Early-Onset Colorectal Cancer Incidence
TUESDAY, May 6, 2025 -- Early-life mutagenic exposure to colibactin-producing bacteria may be associated with the increased incidence of early-onset colorectal cancer, with...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.